Skip to main content Skip to main menu
UF Health University of Florida
The Bannister Lab The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology

Publications

I have authored in total over 95 published patents and peer-reviewed journal articles related to drug discovery and medicinal/organic chemistry.  

An online list of many of my peer-reviewed pubmed-indexed publications can be found at PubMed.gov.

Selected journal publications since 2015 include: 

1.  A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal. Grim, T. W.; Schmid, C. L.; Stahl, E. L.; Pantouli, F.; Ho, J-H.; Acevedo-Canabal, A.; Kennedy, N. M.; Cameron, M. D.; Bannister, T. D.; Bohn, L. M. Nature Neuropsycopharmacology, 2019, published online ahead of print Aug 23, 2019 

2.  The novel small molecule SR18662 efficiently inhibits the growth of colorectal cancer in vitro and in vivo. Kim, J.; Wang, C.; de Sabando, A. R.; Cole, H. L.; Huang, T. J.; Yang, J.; Bannister, T. D.; Yang, V. W.; Bialkowska, A. B. Mol. Cancer Therapeutics, 2019, DOI: 10.1158/1535-7163.MCT-18-1366, epub ahead of print: https://mct.aacrjournals.org/content/early/2019/07/27/1535-7163.MCT-18-1366 

3.  Native Directed Site-Selective δ-C(sp3)–H and δ-C(sp2)–H Arylation of Primary Amines. Lin, H.; Pan, X.; Barsamian, A.; Kamenecka, T. M.; Bannister, T. D. ACS Catal.,2019, 9, 4887–4891.

4.  Inhibitors of Lactate Transport: A Promising Approach in Cancer Drug Discovery. Bannister, T. D. 2019, In: Boffetta, P., Hainaut, P. (Eds.), Encyclopedia of Cancer, 3rd edition, vol. 2, Elsevier, Academic Press, pp. 266–278. http://dx.doi.org/10.1016/B978-0-12-801238-3.64996-6

5.    Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias. Kennedy, N. M.; Schmid, C. L.; Lovell, K. M.; Yue, Z.; Chen, Y-T.; Cameron, M. D.; Bohn, L. M.; Bannister, T. D. J. Med Chem., 2018, 61, 19, 8895-8907. 

6. Chemical Validation and Optimization of Pharmacoperones Targeting Vasopressin Type Two Receptor Mutant. Janovick, J. A.; Spicer, T. P.; Bannister, T. D.; Smith, E.; Ganapathy, V.; Scampavia, L. Biochem J. 2018, 475(18), 2941-2953.

7.  A Rapid Phenotypic Whole-Cell Screening Approach for the Identification of Small-Molecule Inhibitors That Counter β-Lactamase Resistance in Pseudomonas aeruginosa. Collia, D.; Bannister, T. D.; Tan, H.; Jin, S.; Langaee, T.; Shumate, J.;  Scampavia, L.;  Spicer, T. P. SLAS Discov. 2018, (1):55-64. doi: 10.1177/2472555217728489. Epub 2017 Aug 29. PMID: 28850797

8. Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119. Nieto, A.; Fernández-Vega, V.; Spicer, T. P.; Sturchler, E.; Adhikari, P.; Kennedy, N.; Mandat, S.; Chase, P.; Scampavia, L.; Bannister, T.; Hodder, P.; McDonald, P. H. Assay Drug Dev Technol. 2018, 16(5):278-288. PMID: 30019946

9.  Site-​selective γ-​C(sp3)​-​H and γ-​C(sp2)​-​H arylation of free amino esters promoted by a catalytic transient directing group. Lin, H.; Wang, C.; Bannister, T. D.; Kamenecka, T. M. Chemistry – A European Journal (2018), 24(38), 9535-9541.

10.  Bias factor and therapeutic window correlate to predict safer opioid analgesics. Schmid, C. L., Kennedy, N. M.; Ross, N. C.; Lovell, K. M.; Yue, Z.; Morgenweck, J.; Cameron, M. D., Bannister, T. D.; Bohn, L. M. Cell, 2017, 171(5):1165-1175. PMID: 29149605.

11.  Natural Product Synthesis and Drug Discovery: Shortcomings and Successes. Pedzisa, L., Bannister, T. D. Trop J Nat Prod Res, September 2017; 1(3):95-96.

12.  Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias. Janovick, J. A.; Spicer, T. P.; Bannister, T. D.; Scampavia, L.; Conn, P. M. PLoS One, 2017, 12(8):e0181830. PMID: 28767678.

13.  SR-18662: A Potent Colorectal Cancer Growth Inhibitor, Kim, J. M.; Huang, T. J.; de Sabando, A. R.; Yang, V. W.; Bialkowska, A.; Bannister T. D.; Wang, C. Gastroenterology 2017, 152(5):S41.

14.  Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate. Madoux, F.; Dreymuller, D.;  Pettiloud, J. P.;  Santos, R.;  Becker-Pauly, C.; Ludwig, A.;  Fields, G. B.;  Bannister, T.; Spicer, T. P.;  Cudic, M.;  Scampavia, L. D.;  Minond, D. Sci Rep. 2016 6(1):11. doi: 10.1038/s41598-016-0013-4. PMID: 28442704

15.  Identification of Potential Pharmacoperones Capable of Rescuing the Functionality of Misfolded Vasopressin 2 Receptor Involved in Nephrogenic Diabetes Insipidus. Smith, E.; Janovick, J. A.; Bannister, T. D.; Shumate, J.; Scampavia, L.; Conn, P. M.; Spicer, T. P. J Biomol Screen. 2016, 8:824-831. PMID: 27280550.

16.  Receptor antagonism/agonism can be uncoupled from pharmacoperone activity. Janovick J. A.; Spicer T. P.; Smith, E.; Bannister, T. D.; Kenakin, T.; Scampavia, L.; Conn, P. M. Mol Cell Endocrinol. 2016 ;434:176-85. PMID: 27389877

17.  Synthesis and Cytoxicity of Sempervirine and Analogues. Pan, X.; Yang, C.; Cleveland, J. L, Bannister, T. D. Journal of Organic Chemistry 2016, 81(5), 2194-2200.

18.  Tale of Two Protecting Groups—Boc vs SEM—for Directed Lithiation and C–C Bond Formation on a Pyrrolopyridazinone Core, Nair, R. N., Bannister, T. D. Org. Process Res. Dev., 2016, 20 (7), 1370–1376.

19.  Exploiting the co-reliance of tumours upon transport of amino acids and lactate: Gln and Tyr conjugates of MCT1 inhibitors. Nair, R. N.; Mishra, J. K.; Li, F.; Tortosa, M.; Yang, C.; Doherty, J. R.; Cameron, C.; Cleveland, J. L.; Roush, W. R.; Bannister, T. D. Med. Chem. Commun. 2016, 7(5), 900-905.

20.  ML264 – a novel small-molecule compound that potently inhibits growth of colorectal cancer. de Sabando, A. R.; Wang, C.; He, Y.; García-Barros, M.; Kim, J.; Shroyer, K. R.; Bannister, T. D.; Yang, V. W.; B. Bialkowska, A. B. Molecular Cancer Therapeutics,2016, 15(1), 72-83. The article may be accessed at: http://mct.aacrjournals.org/content/early/2015/11/26/1535-7163.MCT-15-0600.abstract

21. Identification of Small Molecules that Disrupt Signaling between ABL and Its Positive Regulator RIN1. Ting, P. Y., Damoiseaux, R.; Titz, B.; Bradley, K. A.; Graeber, T. G.; Fernández-Vega, V.; Bannister, T.D.; Chase, P.; Nair, R.; Scampavia, L.; Hodder, P.; Spicer, T. P.; Colicelli, J. PLoS One 2015, 10(3): e0121833. doi:10.1371 /journal.pone.0121833

22.  Selective Targeting of Extracellular Insulin-Degrading Enzyme by Quasi-Irreversible Thiol-Modifying Inhibitors. Abdul-Hay, S. O.; Bannister, T. D.; Wang, H.; Cameron, M. D.;  Caulfield, T. R., Masson, A.; Bertrand, J.; Howard, E. A.; McGuire, M. P.; Crisafulli, U.; Rosenberry, T. R.; Topper, C. L.; Thompson, C. R.; Schürer, S. C.; Madoux, F.; Hodder, P.; Leissring, M. A. ACS Chem Biol. 2015,10(12):2716-24. doi: 10.1021/acschembio.5b00334. PMID: 26398879

23.  One-Pot Directed Alkylation/Deprotection Strategy for the Synthesis of Substituted Pyrrole[3,4-d]pyridazinones. Nair, R. N.; Bannister, T. D. Eur. J. Org. Chem. 2015, 1764–1770.

24.  Preparation of tetrasubstituted pyrimido[4,5-d]pyrimidine diones. Wang, H.; Wang, C.; Bannister, T. D. Tetrahedron Lett. 2015, 56 (15), 1949–1952.

25.  Identification of Potent Inhibitors of the Trypanosoma brucei Methionyl-tRNS Synthestase via High-Throughput Orthogonal Screening. Pedro-Rosa, L.: Buckner, F. S.; Ranade, R. M.; Eberhardt, C.; Madoux, F.; Gillespie, J. R., Koh, C. Y., Brown, S., Lohse, J., Verlinde, C. L. M., Fan, E., Bannister, T., Scampavia, L., Hol, W. M. G.; Spicer, T.; Hodder, P. J. Journal of Biomolecular Screening 2015, 20(1), 122–130.